Credit Suisse Downgrades Esperion Therapeutics Inc to Underperform with Price Target $10.00

Brokerage firm Credit Suisse Downgrades its rating on Esperion Therapeutics Inc(NASDAQ:ESPR). In a research note issued to the investors, the brokerage major Lowers the price-target to $10.00 per share. The shares have been rated Underperform. Previously, the analysts had a Neutral rating on the shares. The rating by Credit Suisse was issued on Jun 29, 2016.

In a different note, On Jun 29, 2016, JP Morgan said it Downgrades its rating on Esperion Therapeutics Inc. In the research note, the firm Lowers the price-target to $50.00 per share. The shares have been rated ‘Neutral’ by the firm.

Esperion Therapeutics Inc (ESPR) made into the market gainers list on Fridays trading session with the shares advancing 4.76% or 0.47 points. Due to strong positive momentum, the stock ended at $10.35, which is also near the day’s high of $10.5. The stock began the session at $10.15 and the volume stood at 15,66,097 shares. The 52-week high of the shares is $100.98 and the 52 week low is $9.58. The company has a current market capitalization of $233 M and it has 2,25,41,028 shares in outstanding.

Esperion Therapeutics Inc(ESPR) last announced its earnings results on May 4, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-0.65. Analysts had estimated an EPS of $-0.74.

Several Insider Transactions has been reported to the SEC. On May 5, 2016, Timothy M Mayleben (CEO) purchased 7,000 shares at $14.85 per share price.Also, On Mar 2, 2016, Gilbert S Omenn (director) purchased 5,000 shares at $15.28 per share price.On Apr 27, 2015, Dov A Md Goldstein (director) sold 217,469 shares at $107.73 per share price, according to the Form-4 filing with the securities and exchange commission.

Esperion Therapeutics Inc. is a pharmaceutical company focused on developing and commercializing oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Company’s primary activities include conducting research and development activities including nonclinical preclinical and clinical testing performing business and financial planning recruiting personnel and raising capital. ETC-1002 the Company’s lead product candidate is an orally available once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *